Abstract
Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Biomarkers and phenotypic expression in Alzheimer’s disease: exploring the contribution of frailty in the Alzheimer’s Disease Neuroimaging Initiative
GeroScience Open Access 19 November 2020
-
HENA, heterogeneous network-based data set for Alzheimer’s disease
Scientific Data Open Access 14 August 2019
-
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Alzheimer's Research & Therapy Open Access 15 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Blennow, K., de Leon, M.J. & Zetterberg, H. Lancet 368, 387–403 (2006).
Hardy, J. & Selkoe, D.J. Science 297, 353–356 (2002).
Mangialasche, F. et al. Lancet Neurol. 9, 702–716 (2010).
Holmes, C. et al. Lancet 372, 216–223 (2008).
Garcia-Alloza, M. et al. Mol. Neurodegener. 4, 19 (2009).
DeCarli, C. Lancet Neurol. 2, 15–21 (2003).
Petersen, R.C. et al. N. Engl. J. Med. 352, 2379–2388 (2005).
Hansson, O. et al. Lancet Neurol. 5, 228–234 (2006).
Shaw, L.M. et al. Ann. Neurol. 65, 403–413 (2009).
Visser, P.J. et al. Lancet Neurol. 8, 619–627 (2009).
Mattsson, N. et al. J. Am. Med. Assoc. 302, 385–393 (2009).
Frisoni, G.B., Fox, N.C., Jack, C.R. Jr., Scheltens, P. & Thompson, P.M. Nat. Rev. Neurol. 6, 67–77 (2010).
Nordberg, A., Rinne, J.O., Kadir, A. & Langstrom, B. Nat. Rev. Neurol. 6, 78–87 (2010).
Nelson, P.T., Kukull, W.A. & Frosch, M.P. J. Neuropathol. Exp. Neurol. 69, 449–454 (2010).
Kotzbauer, P.T., Trojanowsk, J.Q. & Lee, V.M. J. Mol. Neurosci. 17, 225–232 (2001).
Schneider, J.A., Arvanitakis, Z., Leurgans, S.E. & Bennett, D.A. Ann. Neurol. 66, 200–208 (2009).
Rinne, J.O. et al. Lancet Neurol. 9, 363–372 (2010).
Eriksen, J.L. et al. J. Clin. Invest. 112, 440–449 (2003).
Galasko, D.R. et al. Alzheimer Dis. Assoc. Disord. 21, 292–299 (2007).
Wilcock, G.K. et al. Lancet Neurol. 7, 483–493 (2008).
Green, R.C. et al. J. Am. Med. Assoc. 302, 2557–2564 (2009).
Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Nat. Rev. Neurol. 6, 131–144 (2010).
Bateman, R.J. et al. Ann. Neurol. 66, 48–54 (2009).
Portelius, E. et al. Alzheimers. Res. Ther. 2, 7 (2010).
Blennow, K. et al. Neurosci. Lett. 419, 18–22 (2007).
Zetterberg, H. et al. J. Alzheimers Dis. 12, 255–260 (2007).
Chen, X., Magnotta, V.A., Duff, K., Boles Ponto, L.L. & Schultz, S.K. J. Neuropsychiatry Clin. Neurosci. 18, 178–185 (2006).
Tune, L. et al. Am. J. Geriatr. Psychiatry 11, 169–177 (2003).
Krishnan, K.R. et al. Am. J. Psychiatry 160, 2003–2011 (2003).
Hashimoto, M. et al. Am. J. Psychiatry 162, 676–682 (2005).
Fagan, A.M. et al. Ann. Neurol. 59, 512–519 (2006).
Degerman Gunnarsson, M. et al. Dement. Geriatr. Cogn. Disord. 29, 204–212 (2010).
Hampel, H. et al. Nat. Rev. Drug Discov. 9, 560–574 (2010).
Davidsson, P. & Blennow, K. Int. Pychogeriatr. 10, 11–23 (1998).
Davidsson, P., Puchades, M. & Blennow, K. Electrophoresis 20, 431–437 (1999).
Walsh, D.M. & Selkoe, D.J. J. Neurochem. 101, 1172–1184 (2007).
Fukumoto, H. et al. FASEB J. published online, 10.1096/fj.09-150359 (25 March 2010).
Portelius, E. et al. Neurobiol. Aging published online, 10.1016/j.neurobiolaging.2009.06.002 (14 July 2009).
Portelius, E. et al. Neurodegener. Dis. 6, 258–262 (2009).
Cook, J.J. et al. J. Neurosci. 30, 6743–6750 (2010).
Portelius, E. et al. J. Alzheimers Dis. published online, 10.3233/JAD-2010-100573 (15 July 2010).
Fleisher, A.S. et al. Arch. Neurol. 65, 1031–1038 (2008).
Lannfelt, L. et al. Lancet Neurol. 7, 779–786 (2008).
Gilman, S. et al. Neurology 64, 1553–1562 (2005).
Fox, N.C. et al. Neurology 64, 1563–1572 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares competing financial interests: details accompany the full-text HTML version of the paper at http://www.nature.com/naturemedicine/.
Rights and permissions
About this article
Cite this article
Blennow, K. Biomarkers in Alzheimer's disease drug development. Nat Med 16, 1218–1222 (2010). https://doi.org/10.1038/nm.2221
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2221
This article is cited by
-
Biomarkers and phenotypic expression in Alzheimer’s disease: exploring the contribution of frailty in the Alzheimer’s Disease Neuroimaging Initiative
GeroScience (2021)
-
Invasive and non-invasive therapies for Alzheimer’s disease and other amyloidosis
Biophysical Reviews (2020)
-
HENA, heterogeneous network-based data set for Alzheimer’s disease
Scientific Data (2019)
-
The Binding Mechanisms and Inhibitory Effect of Intravenous Anesthetics on AChE In Vitro and In Vivo: Kinetic Analysis and Molecular Docking
Neurochemical Research (2019)
-
Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis
Cellular and Molecular Life Sciences (2019)